SCHEMBL13126019

SCHEMBL13126019

COc1ccc(-c2cnc3c(-c4ccc(C(=O)O)cc4)cnn3c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.76
FLT1 P17948 3/20 0.70
FLT4 P35916 3/20 0.70
BMP4 P12644 3/20 0.70
BMPR1B O00238 3/20 0.64
BMPR1A P36894 3/20 0.64
ACVRL1 P37023 3/20 0.64
ACVR1 Q04771 3/20 0.64
TGFBR2 P37173 2/20 0.64
PRKAB1 Q9Y478 2/20 0.64
BMPR2 Q13873 1/20 0.64
KMT2A Q03164 1/20 0.60
MAP4K4 O95819 2/20 0.58
PLK4 O00444 1/20 0.58
AURKA O14965 1/20 0.58
DYRK3 O43781 1/20 0.58
NTRK1 P04629 1/20 0.58
INSR P06213 1/20 0.58
CDK1 P06493 1/20 0.58
FGFR1 P11362 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7610618 0.86 KDR (1.00) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL5416682 0.86 KDR (0.67) KDRFLT1FLT4BMP4ACVR1
SCHEMBL4474846 0.84 KDR (0.65) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL3758736 0.83 MAP4K4 (0.57) KDRFLT1FLT4BMP4ACVR1
SCHEMBL2059685 0.83 KDR (1.00) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL7610653 0.80 KDR (1.00) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL13126026 0.79 FLT1 (0.75) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL4477345 0.79 KDR (0.62) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL27218304 0.78 KDR (1.00) KDRFLT1FLT4BMP4BMPR1B
SCHEMBL30508296 0.77 KDR (0.66) KDRFLT1FLT4BMP4BMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240647-A1 Treatment of Alzheimer's Disease and Related Conditions MERCK & CO., INC. 2010-09-23 US disclosed
US-20100240647-A1 Treatment of Alzheimer's Disease and Related Conditions MERCK & CO., INC. 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240647-A1 Treatment of Alzheimer's Disease and Related Conditions MAPT, MAP2, TTBK1 KDR 3689/4885FLT1 3092/4885FLT4 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.